Boston Scientific (BSX) Gains from Investment Securities (2009 - 2026)

Boston Scientific has disclosed Gains from Investment Securities across 10 years of filings, most recently posting -$30.0 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$30.0 million, down 700.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$119.0 million (down 158.7% YoY), and the FY2025 annual result was -$84.0 million, down 1580.0% from the prior year.
• Gains from Investment Securities came in at -$30.0 million for Q1 2026 at Boston Scientific, up from -$95.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $89.0 million in Q4 2022 to a low of -$95.0 million in Q4 2025.
• The 5-year median for Gains from Investment Securities is $8.0 million (2025), against an average of $1.9 million.
• Across the five-year window, Gains from Investment Securities surged 545.0% in 2022 and sank 700.0% in 2026, its largest moves.
• Boston Scientific's Gains from Investment Securities stood at $89.0 million in 2022, then sank by 83.15% to $15.0 million in 2023, then slumped by 300.0% to -$30.0 million in 2024, then plunged by 216.67% to -$95.0 million in 2025, then surged by 68.42% to -$30.0 million in 2026.
• The last three Gains from Investment Securities figures came in at -$30.0 million (Q1 2026), -$95.0 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.